Approval was given to GSK, making its product the first antisense oligonucleotide established for the treatment of chronic hepatitis B.
News|Articles|February 13, 2019
Revcovi for Adenosine Deaminase Severe Combined Immune Deficiency
Author(s)Drew Boxler
Advertisement
Revcovi (elapegademase-lvlr, Lediant Biosciences)
Indications: Adenosine deaminase severe combined immune deficiency (ADA-SCID)
Dosage:
- Starting: 0.4 mg/kg (idea body weight) in 2 intramuscular supplements (0.2 mg/kg twice per week)
- Maintenance dosing: increments of 0.033 mg/kg weekly if...
- trough ADA activity is under 30 mmol/hr/L
- trough deoxyadenosine nucleotides (dAXP) are above 0.02 mmol/L
- the immune reconstitution is inadequate based on the clinical assessment of the patient
Contraindications: N/A
Advertisement
Related to this article
With safety and efficacy profiles aligning with its brand-name formulation, this new patch could be key for women struggling with hormone therapy adherence.
Therapy is aimed at decreasing pathogenic IgA production and immune complex formation as well as managing the effects of existing nephron loss.
This new, nonprescription therapy expands eye relief options for patients in need of apraclonidine eye drop formulations.
Advertisement
Advertisement
Trending on Drug Topics
1
American Pharmacists Month: PBM Reform, Provider Status Key in Stopping Pharmacy Deserts
2
Pfizer Reports Strong Phase 2 Data for 25-Valent Pediatric PCV
3
PBMs Must Now Disclose Fees to Employer Plans Under Final DOL Rule
4
HHS Lets Pharmacies Compound Peptides as FDA Writes Official Rule
5